Related Experiment Videos
[New methods of chemotherapy also for extrapulmonary tuberculosis?]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|October 1, 1978
Summary
Short-term therapy for extrapulmonary tuberculosis is now possible with new drugs like rifampicin and pyrazinamide. A twelve-month treatment regimen, including a three-month continuous phase, is effective for tuberculosis management.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Context:
- Tuberculosis treatment traditionally involves long-term chemotherapy.
- Extrapulmonary tuberculosis management often extends to 18-24 months.
- Debate exists regarding optimal treatment duration for extrapulmonary forms.
Purpose:
- To evaluate the feasibility of shortening treatment duration for extrapulmonary tuberculosis.
- To assess the efficacy of new antitubercular drugs in reducing treatment time.
- To propose a revised therapeutic regimen for extrapulmonary tuberculosis.
Summary:
- Newly developed antitubercular drugs, including rifampicin and pyrazinamide, demonstrate efficacy against dormant bacteria (persisters).
- A twelve-month short-term therapy regimen is proposed for extrapulmonary tuberculosis, based on pulmonary treatment experiences.
- This regimen features a three-month continuous drug application followed by a twice-weekly intermittent phase.
Impact:
- Shortened treatment duration benefits patient compliance and reduces potential toxicity.
- Effective targeting of persister cells allows for reduced overall therapy time.
- This approach offers a more patient-centered strategy for managing extrapulmonary tuberculosis.